BTIG lowered the firm’s price target on Haemonetics (HAE) to $85 from $105 and keeps a Buy rating on the shares. The company’s Q1 beat was driven by the Plasma segment and helped by Blood Management Tech and Blood Center Sales, the analyst tells investors in a research note. The firm added that it remains constructive on Haemonetics but needs to see improvement in the Vascade franchise throughout this fiscal year, and reduced its price/equity multiple to 15x from 18.5x, roughly in line with the media of the comp group, to arrive at its new price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics’ Strong Financial Performance and Strategic Adjustments Justify Buy Rating Despite Challenges
- Haemonetics price target lowered to $68 from $84 at Needham
- Haemonetics backs FY26 adjusted EPS view $4.70-$5.10, consensus $4.87
- Haemonetics reports Q1 EPS $1.10, consensus $1.02
- HAE Upcoming Earnings Report: What to Expect?